



Comprehensive care. Uncompromising quality.

Our urologic radiology is a subspecialised service that assists in the diagnosis and treatment of diseases or conditions such as urinary tract infections, kidney stones, bladder control problems, and prostate cancer.

Services available across our network of clinics include:

- MRI for highly detailed imaging of soft tissues, blood vessels and sensitive to diseases such as tumours
- Prostate, renal and testes
 ultrasound simple and painless
 way to evaluate bladder, certain
 conditions of the prostate and the
 kidney
- Renal CT imaging rapidly acquires images of the kidneys, ureters, and bladder - especially useful to detect stones within the urinary system
- Nuclear medicine renal scan for information on blood flow and function of the kidneys
- PET PSMA ffor precise detection and staging of prostate cancer, both within the prostate and to see if there has been spread (metastasis)

For more information on our services please contact your local I-MED Radiology clinic or visit our website i-med.com.au

Prostate cancer

Prostate cancer is the most diagnosed cancer among males, especially after age 65.

MRI is considered the gold standard for non-invasive visualisation of the prostate and surrounding tissues. MRI provides a greater level of diagnostic confidence to accurately detect and stage prostate cancer appropriately and provide a roadmap for treatment and patient management.

PSMA PET uses a PET-sensitive agent, called 68Ga-PSMA-11, which binds to prostate cancer cells to help localise prostate cancer cells. It offers a precise method for the detection of prostate cancer, both within the prostate gland and when it has spread outside the prostate. The PSMA PET scan can identify cancer that is often missed by current standard-of-care imaging techniques.

Medicare indications for prostate MRI and PET PSMA

Medicare rebates for PET available to specialists/ consultants. For MRI, urologists, radiation oncologists and medical oncologists.

MR

Item 63541: for the diagnosis of prostate cancer **Item 63543:** active surveillance of patients with a proven diagnosis following biopsy histopathology.

PE1

Item 61563: initial staging of intermediate to highrisk prostate adenocarcinoma (previously untreated patient)

Item 61564: restaging of recurrent prostate adenocarcinoma (previously undergone prior locoregional therapy)